Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restricted, soft pan-JAK inhibitor, for the treatment of atopic dermatitis (AD). This randomized, double-blind, vehicle-controlled Phase II study evaluated the efficacy and safety of topical […]

First AltĀ® Marks Three Years of Growth – Redefining Safety, Innovation, and Equity in Alternative Student Transportation

First Student, the nation's leader in school transportation, is raising alternative transportation driver standards to ensure every child receives the same high level of care and safety. First Student, the company setting the standard for innovation and transforming the school transportation industry, today celebrates the third anniversary of First Alt®, its alternative transportation service offering.

The Home Depot Launches AI-Powered Blueprint Takeoffs Tool to Help Pros Stay on Time and on Budget

AI technology expedites single-family projects by delivering faster, more accurate blueprint takeoffs The Home Depot, the world's largest home improvement retailer, launched a Blueprint Takeoffs solution, a new AI-powered tool that is designed to provide professional renovators, remodelers and builders with faster, more accurate and cost-effective material lists and estimates – also known as takeoffs

Interplay Learning named to Deloitte’s 2025 Technology Fast 500 list

The innovator in skilled trades training and upskilling has been honored among the fastest-growing companies in the technology space Interplay Learning, the leading provider of immersive skilled trades training, has been named to the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in

METRO REPORTS 2025 FOURTH QUARTER RESULTS

METRO INC. (TSX: MRU) today announced its results for the fourth quarter of Fiscal 2025 ended September 27, 2025. 2025 FOURTH QUARTER HIGHLIGHTS — Sales of $5,108.7 million, up 3.4% — Food same-store sales(1) up 1.6% — Pharmacy same-store sales(1) up 4.8% — Net earnings of $217.0million, down 1.3% and adjusted net earnings(1) of $246.0million,

Economic pressures have left over 80% of Canadian youth feeling stressed and anxious about their future – yet barriers to accessing mental health support persist

New report from GreenShield and Mental Health Research Canada highlights the urgent need for more accessible, inclusive solutions to support youth mental health. A new survey from GreenShield, Canada's only national non-profit health care and insurance organization, conducted in partnership with Mental Health Research Canada (MHRC), reveals that over 80% of Canadian youth are overwhelmed

Canadian businesses adopting AI, but few are seeing ROI

Only two per cent of business leaders reported a return on their AI investments, KPMG data shows While a majority of Canadian business leaders say their organizations are using generative artificial intelligence, few have integrated it fully across their operations and only a small fraction are seeing a return on their investments, new KPMG Canada

Silverpush Announces Creative Studio Powered by Airtory to Scale Social Video for YouTube and CTV Advertising

Silverpush Announces Creative Studio Powered by Airtory to Scale Social Video for YouTube and CTV Advertising GlobeNewswire November 19, 2025 LONDON, Nov. 19, 2025 (GLOBE NEWSWIRE) — Silverpush, the contextual intelligence company, announced today (November 19, 2025) a strategic partnership with Airtory, a leading creative ad tech platform to enable brands and agencies to seamlessly

Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock

Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock GlobeNewswire November 19, 2025 SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the

Libtayo(R) (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Libtayo(R) (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation GlobeNewswire November 19, 2025 Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival

Scroll to Top